What is the 13F Pro Quality Score for CORT?

13F Pro ranks CORCEPT THERAPEUTICS INC (CORT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CORT's current score at https://13fpro.ai/company/CORT (free sign-up required for the full ranking).

Which hedge funds own the most CORT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CORT include BlackRock,, INGALLS & SNYDER, RENAISSANCE TECHNOLOGIES. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/CORT as soon as new 13F filings post.

Where does 13F Pro source CORT data?

All CORCEPT THERAPEUTICS INC fundamentals and ownership data come directly from SEC EDGAR. CORCEPT THERAPEUTICS INC files with the SEC under CIK 1088856. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CORT in?

CORCEPT THERAPEUTICS INC (CORT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CORT research updated on 13F Pro?

CORT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CORCEPT THERAPEUTICS INC(CORT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1088856 CORT stock profile & AI dashboard →

13F Pro Quality Score

57.8/100

Rank #1,070 of 2,960 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

82.6/100

Profitability

39.1/100

Balance Sheet

75.5/100

Earnings Quality

83.8/100

Free Cash Flow

61.4/100

Institutional Flow

37.4/100

Revenue Scale

46.8/100

Dilution Risk

15.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why CORT Scores 58/100

exact factor attribution · 2026-09-10

CORT's composite is driven by revenue growth and earnings quality, held back by earnings growth and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.5 pts

83th pct

Earnings quality

+3.4 pts

84th pct

Capital efficiency

+2.5 pts

76th pct

Free cash flow

+1.7 pts

61th pct

Scale

-0.5 pts

47th pct

Institutional flow

-0.6 pts

37th pct

Profitability

-1.6 pts

39th pct

Shareholder dilution

-1.8 pts

15th pct

Earnings growth

-1.9 pts

12th pct

Latest change (2026-07-30): 55 → 54 · ↓ Revenue growth 82→67

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

CORT Stock Analysis & AI Quality Score

Data updated 2026-09-10

AI stock analysis and institutional research for CORCEPT THERAPEUTICS INC (CORT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CORT at 57.8/100 on a 32-signal composite quality model, placing it at rank #1,070 of 2,960 stocks — the top half of the AI-ranked universe. CORT scores in the top quartile across earnings quality (83.8), revenue growth (82.6), balance sheet strength (75.5). Areas of concern include institutional flow (37.4) and profitability (39.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CORCEPT THERAPEUTICS INC reports quarterly revenue of $256.1M, net income of $43.0M, free cash flow of $31.0M. Top institutional holders of CORT by reported 13-F value include BlackRock, INGALLS & SNYDER, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. CORT trades on the Nasdaq exchange and files with the SEC under CIK 1088856. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CORT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CORCEPT THERAPEUTICS INC directly from SEC EDGAR. CORCEPT THERAPEUTICS INC's 13F Pro composite quality score has ranged between 54 and 77 since 2021, currently 57.8 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$256.1M

Net Income

Q2 2026

$43.0M

Free Cash Flow

Q2 2026

$31.0M

ROIC

Q2 2026

23.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+12.8% YoY

$761.4MFY 2025

FY22 $401.9MFY23 $482.4MFY24 $675.0MFY25 $761.4M

Net Income

-29.4% YoY

$99.7MFY 2025

FY22 $101.4MFY23 $106.1MFY24 $141.2MFY25 $99.7M

Operating Income

-67.3% YoY

$44.8MFY 2025

FY22 $112.6MFY23 $107.3MFY24 $137.0MFY25 $44.8M

EPS (Diluted)

-33.3% YoY

$0.82FY 2025

FY22 $0.87FY23 $0.94FY24 $1.23FY25 $0.82

Total Assets

-0.5% YoY

$836.7MFY 2025

FY22 $583.4MFY23 $621.5MFY24 $840.6MFY25 $836.7M

Op. Cash Flow

-28.4% YoY

$142.0MFY 2025

FY22 $120.3MFY23 $126.7MFY24 $198.3MFY25 $142.0M

Free Cash Flow

-27.7% YoY

$141.8MFY 2025

FY22 $119.9MFY23 $126.5MFY24 $196.1MFY25 $141.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$761.4M +12.8%	$675.0M +39.9%	$482.4M +20.0%	$401.9M +9.8%	$366.0M +3.4%	$353.9M
Net Income	$99.7M -29.4%	$141.2M +33.0%	$106.1M +4.7%	$101.4M -9.9%	$112.5M +6.1%	$106.0M
Operating Income	$44.8M -67.3%	$137.0M +27.7%	$107.3M -4.8%	$112.6M -9.5%	$124.5M -2.9%	$128.2M
EPS (Diluted)	$0.82 -33.3%	$1.23 +30.9%	$0.94 +8.0%	$0.87 -2.2%	$0.89 +4.7%	$0.85
Total Assets	$836.7M -0.5%	$840.6M +35.2%	$621.5M +6.5%	$583.4M +37.7%	$423.8M -25.9%	$571.7M
Operating Cash Flow	$142.0M -28.4%	$198.3M +56.5%	$126.7M +5.3%	$120.3M -28.3%	$167.9M +10.5%	$152.0M
Free Cash Flow	$141.8M -27.7%	$196.1M +55.0%	$126.5M +5.5%	$119.9M -28.4%	$167.4M +11.1%	$150.7M

Get alerted when CORT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CORCEPT THERAPEUTICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CORT

BlackRock, Inc.
$1.1B12,432,023 sh
INGALLS & SNYDER LLC
$689.9M7,934,507 sh
RENAISSANCE TECHNOLOGIES LLC
$457.5M5,261,628 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$438.6M5,044,638 sh
VANGUARD CAPITAL MANAGEMENT LLC
$362.8M4,172,482 sh
Parallel Advisors, LLC
$344.5M3,962,177 sh
FMR LLC
$290.2M3,337,618 sh
STATE STREET CORP
$285.2M3,279,381 sh
AQR CAPITAL MANAGEMENT LLC
$224.6M2,582,561 sh
GEODE CAPITAL MANAGEMENT, LLC
$220.2M2,532,198 sh

Fund	Value	Shares
BlackRock, Inc.	$1.1B	12,432,023
INGALLS & SNYDER LLC	$689.9M	7,934,507
RENAISSANCE TECHNOLOGIES LLC	$457.5M	5,261,628
VANGUARD PORTFOLIO MANAGEMENT LLC	$438.6M	5,044,638
VANGUARD CAPITAL MANAGEMENT LLC	$362.8M	4,172,482
Parallel Advisors, LLC	$344.5M	3,962,177
FMR LLC	$290.2M	3,337,618
STATE STREET CORP	$285.2M	3,279,381
AQR CAPITAL MANAGEMENT LLC	$224.6M	2,582,561
GEODE CAPITAL MANAGEMENT, LLC	$220.2M	2,532,198

Companies Similar to CORT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ALKS

Alkermes plc.

AI score

Similar quality profile · 11 shared holders

Rock Springs Capital Management LP ROYCE & ASSOCIATES LP Birchview Capital, LP

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 13 shared holders

TANG CAPITAL MANAGEMENT LLC KENNEDY CAPITAL MANAGEMENT LLC Alberta Investment Management Corp

SUPN

SUPERNUS PHARMACEUTICALS, INC.

AI score

Similar quality profile · 14 shared holders

Susquehanna Portfolio Strategies, LLC Hennion & Walsh Asset Management, Inc.Bridge City Capital, LLC

PODD

INSULET CORP

AI score

Similar quality profile · 6 shared holders

Voleon Capital Management LP Bridgewater Associates, LP Linden Thomas Advisory Services, LLC

COO

COOPER COMPANIES, INC.

AI score

Similar quality profile · 6 shared holders

Boston Trust Walden Corp Susquehanna Portfolio Strategies, LLC ROYCE & ASSOCIATES LP

CHE

CHEMED CORP

AI score

Similar quality profile · 11 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.Boston Trust Walden Corp KENNEDY CAPITAL MANAGEMENT LLC

ALGN

ALIGN TECHNOLOGY INC

AI score

Similar quality profile · 5 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Bridgewater Associates, LP Dakota Wealth Management

ATRC

AtriCure, Inc.

AI score

Similar quality profile · 6 shared holders

KENNEDY CAPITAL MANAGEMENT LLC Susquehanna Portfolio Strategies, LLC Bridgewater Associates, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CORT on your watchlist

Track score changes the day CORCEPT THERAPEUTICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CORT a good stock to buy?

13F Pro's AI-powered analysis of CORCEPT THERAPEUTICS INC (CORT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CORT are available on the CORT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CORT is classified as a large company.

Which hedge funds own CORT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CORT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CORCEPT THERAPEUTICS INC's investment landscape.